Author Index for Volume 24

Abdalla, M, 736
ADAPT investigators, 462
Anbar, D, 51
Anderson, J, 702
Anderson, K, 39
Angiotensin-Converting Enzyme Inhibition in Progressive Renal Disease (AIPRD) Study Group, 324
Apfel, CC, 736
AVID Investigators, 341

Babiker, A, 481, 643
Bain, RP, 224
Baker, RS, 294
Bangdiwala, SI, 78
Barnett, M, 39
Bautista, OM, 224
Beanlands, R, 776
Benard, F, 776
BENEDICT Group, 442
Berger, VW, 156
Berman, N, 422
Bernardo, J, 245
Bhandari, M, 719
Biedler, A, 736
Black, S, 643
Bock, N, 245
Boe, K, 422
Bots, ML, 752
Bowen, DJ, 39
Braun, TM, 669
Brawer, MK, 224
Breese, P, 245
Breitfeld, PP, 702
Broderick, JE, 182
Brown, MB, 629
Brown, ST, 481
Brubaker, L, 629
Buchanan, SL, 289S
Buckelew, JM, 570
Burman, W, 245

Califf, RM, 256
Cameron, W, 481
Carroll, KJ, 682
CAST Investigators, 341
Chacon, FR, 289S
Chappell, R, 135, 506
Charleston, S, 643
Chen, YHJ, 16
Chen-Mok, M, 78
Cheung, Y-B, 110
Children's Amalgam Trial Study Group, 795
Chlebowski, RT, 422
Chung, Y-FA, 110
Clark, M, 591
Clayton, D, 66
Clipp, EC, 206
Coates, G, 776
Cohen, HJ, 206
Collins, JF, 71, 726, 269S, 277S, 298S, 306S, 316S
Connelly, LB, 544
Copas, A, 643
Crawford, ED, 224
Crist, WM, 702
CTNS Study Group, 815
Cundiff, G, 629

DeGruttola, V, 122
de Haan, RJ, 390
deKemp, RA, 776
Delgado-Herrera, L, 51
DeMets, DL, 16, 256
Denes, P, 341
Demark-Wahnefried, W, 206
De Serres, G, 99
Dickersin, K, 294, 591
Digitalis Investigation Group (DIG) Investigators, 726, 269S, 277S, 289S, 298S, 306S, 316S
DiRienzo, AG, 122
Dominik, R, 78
Donovan, JL, 272
Duval, B, 99

Egan, D, 269S, 277S, 298S, 316S
Ellenberg, SS, 201, 585
Ettinger, WH, 462
Evans, GW, 752

Fallen, E, 776
Feldon, SE, 294
Ferrara, JLM, 669
Feussner, JR, 570
Fine, JP, 135
Fine, P, 629
Forrest, S, 643
Frick, KD, 591
Friedman, L, 341
Fye, CL, 289S

Gagne, WH, 289S
Ganju, J, 167, 830
Garg, R, 269S, 277S, 289S, 298S, 306S, 316S
Gazzard, B, 481
Geller, N, 269S, 316S
Giatras, I, 324
Gilpin, AMK, 92
Glas, CAW, 390
Gönen, M, 355
Goodman, G, 39
Goodman, SN, 256
Grambsch, PM, 105
Granadier, RJ, 294
Granek, I, 422
Grobbee, DE, 752

Haakenson, CM, 570
Hallstrom, A, 341
Hamdy, FC, 272
Hashimoto, S, 560
Hays, M, 78
Heller, G, 353
Helmond, FA, 752
Hendry, P, 776
Hillman, DW, 85
Hinotsu, S, 560
Holbrook, JT, 92
Holman, R, 390
Holodniy, M, 481
Hooper, FJ, 294
Horney, A, 277S
Horney, RA, 726

Controlled Clinical Trials 24:833–835 (2003)

© Elsevier Inc. 2003

360 Park Avenue South, New York, NY 10010

0197-2456/03/$–see front matter

Howell, CL, 726, 277S, 306S
Huber, M, 422
Hufford, MR, 182
Humen, D, 776
Hung, HMJ, 147
Hunsberger, S, 4
Huo, D, 506

Iafrate, RP, 256
Irsula, B, 78
Ischemic Optic Neuropathy Decompression Trial Research Group, 294
Iwanochko, RM, 776

Jabs, DA, 92
Jackson, M, 422
Jacoby, A, 272
Jafar, TH, 324
Jarjoura, D, 306
Ji, M, 283
Jiang, H, 135
Johns, A, 591
Johnson, AM, 643
Jones, LA, 711
Jones, MS, 289S
Juritz, J, 440

Kaplan, SA, 224
Karim, T, 324
Karrison, TG, 506
Kawado, M, 560
Kelman, S, 294
Kent, E, 298S
Kirk, G, 277S
Korttila, K, 736
Kosmorsky, GS, 294
Kranke, P, 736
Kusek, JW, 224
Kyriakides, TC, 481

Lan, KKG, 16
Landa, M, 324
Langenberg, P, 591
Leece, P, 719
Lepor, H, 224
Levey, AS, 324
Levine, JE, 669
Liu, Q, 4
Liuni, C, 298S
Loeser, RF, 462
Look AHEAD Research Group, 610
Louis, TA, 85

Machin, D, 110
Magder, LS, 411
Makarewicz, VA, 156
Martin, S, 298S
Mathew, J, 316S
Matsuyama, Y, 560
Matthews, JNS, 200
McBride, KH, 752
McCarney, R, 731
McConnell, JD, 224
McSherry, F, 277S
Mehrotra, DV, 167, 830
Meijer, R, 752
Meinert, CL, 92
Messier, SP, 462
Migrino, RQ, 501
Milas, C, 422
Miller, G, 224
Miller, GD, 462
Mills, N, 272
Morey, MC, 206
Morgan, CC, 523
Morgan, T, 462
Morris, M, 341
Morse, MA, 256
MTOPS Research Group, 224
Munro, M, 591
Mutti, DO, 711

Neal, DE, 272
Neaton, JD, 1, 2, 109, 667
Nelson, DK, 256
Nichol, G, 776
Nyberg, LM, Jr, 224
Nygaard, I, 629

Oakley, A, 643
Oden, NL, 28
Ohashi, Y, 560
Omenn, G, 39
OPAL Investigators, 752
OPTIMA Study Team, 481

PARR-2 Investigators, 776
Paskett, ED, 752
Peipert, JF, 591
Pelvic Floor Disorders Network, 629
Petruckevitch, A, 643
Phelps, DL, 28
Philbin, E, 316S
Pieper, CF, 206
Pocock, SJ, 736
Powell, C, 39
Proschan, MA, 4

Qu, RP, 436

Racine, N, 776
Raisch, DW, 570, 289S
Reddy, M, 324
Rejeski, WJ, 462
Rezvani, A, 156
Richter, H, 629
Riley, W, 752
Rizo-Patron, C, 341
Roewer, N, 736
Ross, H, 776
Ruddy, TD, 776

Sarr, M, 589
Sather, MR, 570, 289S
Schechter, MT, 481
Scheifele, D, 99
Schemitsch, E, 719
Scherer, R, 294, 591
Schmid, CH, 324
Schwartz, JE, 182
Seiff, SR, 294
Sevick, MA, 462
Shiffman, S, 182
Sihelnik, SA, 224
Singer, J, 481
Skowronski, DM, 99
Sloane, R, 206
Smith, M, 272
Snetselaar, L, 422
Snyder, DC, 206
Sokal, DC, 78
Song, JX, 378
Spence, E, 277S
Spivak, J, 422
Sprague, S, 719
S.P.R.I.N.T. Investigators, 719
Stark, PC, 324
Stephenson, JM, 643
Stinnett, S, 277S
Stone, AA, 182
STOP-DUB Research Group, 591
STOP-ROP Multicenter Study Group, 28
Strange, V, 643
Studies of Ocular Complications of AIDS Research Group, 92
Sugarman, J, 256
Swiontkowski, MF, 719

Tai, B-C, 110
Tan, S-B, 110
Tang, M-L, 364
Teo, KK, 306S
Thornquist, M, 39
Topol, EJ, 501
Tornetta, P, III, 719
Tuberculosis Trials Consortium, 245

Ullrich, F, 702

Vernon, A, 245
Vickers, AJ, 731
Visco, A, 629

Walline, JJ, 711
Wang, S-J, 147
Wassell, JT, 378
Weber, A, 591, 629
Weir, AB, 201
Weis, S, 245
Wells, G, 776
Wheatley, K, 66
Williamson, JD, 462
Williford, WO, 269S, 277S, 289S, 306S
Wittes, J, 256

Xiong, C, 283

Yamaguchi, T, 560
Yan, Y, 283
Youle, M, 481
Yusuf, S, 269S, 277S, 289S, 316S

Zadnik, K, 711
Zheng, H, 436
Zyczynski, H, 629

ELSEVIER

Subject Index for Volume 24

ABSTRACTS
Third joint meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics, 43S

ADAPTIVE DESIGN
Practical midcourse sample size modification in clinical trials, 4

ADHERENCE/COMPLIANCE
Patient compliance with paper and electronic diaries, 182
Research staff turnover and participant adherence in the Women's Health Initiative, 422

AIDS/HIV
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial, 481
Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial, 92
Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142, 122
DSMB case study: decision making when a similar clinical trial is stopped early, 85
Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout, 135

ANESTHETICS AND ANTIEMETICS
An International Multicenter Protocol to Assess the single and combined benefits of antiemetic interventions in a Controlled clinical Trial of a $2 \times 2 \times 2 \times 2 \times 2 \times 2$ factorial design (IMPACT), 736

ARRHYTHMIA
Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST) and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID), 341

AUTOIMMUNE DISEASE
A model for the interim analysis process: a case study, 51

BIAS
Estimation following group-sequential response-adaptive clinical trials, 523

BOOK REVIEWS
Analysis of Failure and Survival Data, 353
Data Monitoring Committees in Clinical Trials: A Practical Perspective, 105
Drug Safety Evaluation, 201
A Manager's Guide to the Design and Conduct of Clinical Trials, 589
Randomization in Clinical Trials: Theory and Practice, 200
Statistical Methods in Medical Research fourth edition, 440

CANCER
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization, 66
Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma, 110
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors, 206
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer, 355

Controlled Clinical Trials 22:836–842 (2003)
© Elsevier Inc. 2003
360 Park Avenue South, New York, NY 10010

0197-2456/03/$–see front matter

Stopping the active intervention: CARET, 39
Web-based decision support for clinical trial eligibility determination in an international clinical trials network, 702

CARDIOVASCULAR DISEASE
Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods, 776
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes, 610
The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics, 752

CHILDREN
The Children's Amalgam Trial: design and methods, 795
A school-based randomized controlled trial of peer-led sex education in England, 643
Statistical issues related to early closure of STOP-ROP, a group-sequential trial, 28
Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study, 711
Web-based decision support for clinical trial eligibility determination in an international clinical trials network, 702

CLOSEOUT ACTIVITIES
Determination of vital status at the end of the DIG trial, 726
Stopping the active intervention: CARET, 39

CLUSTER SAMPLES
Balancing the number and size of sites: an economic approach to the optimal design of cluster samples, 544

COCHRAN'S STATISTIC
Sample size for K 2 × 2 tables in equivalence studies using Cochran's statistic, 378

CONSENT
The effects of local review on informed consent documents from a multicenter clinical trials consortium, 245

CONTACT LENS
Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study, 711

CONTROLS
Crossing controls to treatment in repeated-measures trials, 306

COORDINATING CENTER
The role of the data coordinating center in the DIG trial, 277S
The role of the data coordinating center in the IRB review and approval process: the DIG trial experience, 306S
The role of the pharmacy coordinating center in the DIG trial, 289S
The use of regional coordinating centers in large clinical trials: the DIG trial, 298S

CROSSOVER DESIGNS
Sample size calculation for bioequivalence studies with high-order crossover designs, 436

CYTOMEGALOVIRUS
Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial, 92
DSMB case study: decision making when a similar clinical trial is stopped early, 85

DATA AND SAFETY MONITORING BOARD (DSMB)
Be skeptical about unexpected large apparent treatment effects: the case

of an MRC AML12 randomization, 66
Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial, 92
Data and safety monitoring board issues raised in the VA Status Epilepticus Study, 71
DSMB case study: decision making when a similar clinical trial is stopped early, 85
A matter of life and death? The Heart Protection Study and protection of clinical trial participants, 501
A model for the interim analysis process: a case study, 51
Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis, 16
Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies Program, 570
Statistical issues related to early closure of STOP-ROP, a group-sequential trial, 28
Stopping the active intervention: CARET, 39
Termination of a randomized controlled trial of two vasectomy techniques, 78
Toward protecting the safety of participants in clinical trials, 256
Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications, 99

DATA VERIFICATION
A comparison of error detection rates between the reading aloud method and the double data entry method, 560

DECISION SUPPORT TOOL
Web-based decision support for clinical trial eligibility determination in an international clinical trials network, 702

DENTAL RESTORATION
The Children's Amalgam Trial: design and methods, 795

DESIGN PAPERS. *See also* LARGE SIMPLE TRIAL
The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results, 462
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics, 442
The Children's Amalgam Trial: design and methods, 795
Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods, 776
An International Multicenter Protocol to Assess the single and combined benefits of antiemetic interventions in a Controlled clinical Trial of a $2 \times 2 \times 2 \times 2 \times 2 \times 2$ factorial design (IMPACT), 736
The Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract (CTNS): design implications. CTNS report no. 1, 815
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors, 206
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes, 610
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial, 481
The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics, 752
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods, 629
A school-based randomized controlled trial of peer-led sex education in England, 643
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial, 224
Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleed-

ing (STOP-DUB): design and methods, 591

DIABETES
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics, 442
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes, 610

DIARIES
Patient compliance with paper and electronic diaries, 182

DOSE REASSIGNMENT
Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM, 669

ENDPOINT
Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142, 122
Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout, 135
Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis, 16

ETHICS
Are all monitoring boundaries equally ethical? 585
A matter of life and death? The Heart Protection Study and protection of clinical trial participants, 501
Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies Program, 570
Toward protecting the safety of participants in clinical trials, 256

FOLLOW-UP
Determination of vital status at the end of the DIG trial, 726
Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery, 719
Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study, 711
Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year, 731

GOOD CLINICAL PRACTICE
Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies Program, 570

INSTITUTIONAL REVIEW BOARD
The effects of local review on informed consent documents from a multicenter clinical trials consortium, 245
The role of the data coordinating center in the IRB review and approval process: the DIG trial experience, 306S
Toward protecting the safety of participants in clinical trials, 256

INTERIM ANALYSIS
Are all monitoring boundaries equally ethical? 585
Estimation following group-sequential response-adaptive clinical trials, 523
A group sequential, response-adaptive design for randomized clinical trials, 506
A model for the interim analysis process: a case study, 51
Termination of a randomized controlled trial of two vasectomy techniques, 78

ITEM RESPONSE THEORY
Power analysis in randomized clinical trials based on item response theory, 390

LARGE SIMPLE TRIAL
Determination of vital status at the end of the DIG trial, 726

Key personnel of DIG trial, 327S
Lessons learned from the DIG trial, 316S
Overview of the DIG trial, 269S
The role of the data coordinating center in the DIG trial, 277S
The role of the data coordinating center in the IRB review and approval process: the DIG trial experience, 306S
The role of the pharmacy coordinating center in the DIG trial, 289S
The use of regional coordinating centers in large clinical trials: the DIG trial, 298S

LIFESTYLE INTERVENTION
The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results, 462
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors, 206
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes, 610
Sample sizes for comparing means of two lifetime distributions with type II censored data: application in an aging intervention study, 283
A school-based randomized controlled trial of peer-led sex education in England, 643

META-ANALYSIS
Constructing a database of individual clinical trials for longitudinal analysis, 324

MISSING DATA
Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios, and risk differences, 411
Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year, 731

MORTALITY
Data and safety monitoring board issues raised in the VA Status Epilepticus Study, 71
Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST) and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID), 341
Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout, 135
A matter of life and death? The Heart Protection Study and protection of clinical trial participants, 501
Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis, 16

MULTICENTER TRIALS
The effects of local review on informed consent documents from a multicenter clinical trials consortium, 245
Stratified experiments reexamined with emphasis on multicenter trials, 167; correction, 830

NONINFERIORITY
Assessing treatment efficacy in noninferiority trials, 147
Matched-pair noninferiority trials using rate ratio: a comparison of current methods and sample size refinement, 364

PAIN, CHRONIC
Patient compliance with paper and electronic diaries, 182

PRIOR ELICITATION
Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma, 110

QUALITY ASSURANCE
Surgical quality assurance in the Ischemic Optic Neuropathy Decompression Trial (IONDT), 294

RECRUITMENT
Data and safety monitoring board issues raised in the VA Status Epilepticus Study, 71

Direct effect on validity of response run-in selection in clinical trials, 156
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study, 272
Statistical issues related to early closure of STOP-ROP, a group-sequential trial, 28
Web-based decision support for clinical trial eligibility determination in an international clinical trials network, 702

REGRESSION
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer, 355

RENAL DISEASE
Constructing a database of individual clinical trials for longitudinal analysis, 324

REPEATED-MEASURES TRIAL
Crossing controls to treatment in repeated-measures trials, 306

RESPONSE-ADAPTIVE DESIGN
Estimation following group-sequential response-adaptive clinical trials, 523
A group sequential, response-adaptive design for randomized clinical trials, 506

RUN-IN
Direct effect on validity of response run-in selection in clinical trials, 156
Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study, 711

SAMPLE SIZE
Balancing the number and size of sites: an economic approach to the optimal design of cluster samples, 544
A group sequential, response-adaptive design for randomized clinical trials, 506
Matched-pair noninferiority trials using rate ratio: a comparison of current methods and sample size refinement, 364
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer, 355
Power analysis in randomized clinical trials based on item response theory, 390
Practical midcourse sample size modification in clinical trials, 4
Sample size calculation for bioequivalence studies with high-order crossover designs, 436
Sample size for K 2×2 tables in equivalence studies using Cochran's statistic, 378
Sample sizes for comparing means of two lifetime distributions with type II censored data: application in an aging intervention study, 283
Stratified experiments reexamined with emphasis on multicenter trials, 167; correction, 830

SIMULATION STUDY
Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142, 122
Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM, 669
Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout, 135
Estimation following group-sequential response-adaptive clinical trials, 523
A group sequential, response-adaptive design for randomized clinical trials, 506
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer, 355

STAFF TURNOVER
Research staff turnover and participant adherence in the Women's Health Initiative, 422

STOPPING RULES
Are all monitoring boundaries equally ethical? 585
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization, 66

Statistical issues related to early closure of STOP-ROP, a group-sequential trial, 28
Stopping the active intervention: CARET, 39
Termination of a randomized controlled trial of two vasectomy techniques, 78

SURGERY
Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma, 110
An International Multicenter Protocol to Assess the single and combined benefits of antiemetic interventions in a Controlled clinical Trial of a $2 \times 2 \times 2 \times 2 \times 2 \times 2$ factorial design (IMPACT), 736
Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery, 719
A matter of life and death? The Heart Protection Study and protection of clinical trial participants, 501
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods, 629
Surgical quality assurance in the Ischemic Optic Neuropathy Decompression Trial (IONDT), 294
Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods, 591

TWO-STAGE DESIGN
Practical midcourse sample size modification in clinical trials, 4

WEIBULL MODEL
On the use and utility of the Weibull model in the analysis of survival data, 682
Sample sizes for comparing means of two lifetime distributions with type II censored data: application in an aging intervention study, 283

WOMEN'S HEALTH
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors, 206
The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics, 752
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods, 629
Research staff turnover and participant adherence in the Women's Health Initiative, 422
Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods, 591